ArticleFrontiers in bioinformatics2026
A realistic simulation-based benchmark of microbiome normalization in sample stratification and taxa-level analysis.
Article in Frontiers in bioinformatics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Motivation: Normalization is a critical step in microbiome studies because sequencing depth and sparsity can strongly affect downstream analyses. In real datasets, however, the underlying biological signal is unknown, making it difficult to determine whether a normalization method preserves true group differences or introduces distortions. To address this problem in a way that remains relevant to real applications, we developed a simulation-based evaluation framework informed by real microbiome data. The framework generates realistic datasets with known ground truth and enables quantitative comparison of normalization methods at both the sample and taxa levels. Results: Method performance depended on taxonomic resolution and on whether sequencing depth was confounded with group structure. In our case study, model-based normalization-factor methods, particularly edgeR-TMM and, in some settings, DESeq2, gave the closest match to the simulated biological contrast, indicating better recovery of taxa-level differences while preserving sample-level separation. TSS and rarefaction were often the next-best performers. Shannon diversity analyses further showed that sequencing-depth differences alone could create false-positive group differences for several methods, whereas rarefaction remained closest to nominal Type I error control. These results also showed that visual or statistical sample separation alone was not sufficient to judge normalization performance, because apparent group differences did not always correspond to correct taxa-level recovery. Rather than identifying a universally best method, the proposed framework provides a coherent strategy for evaluating existing and new normalization approaches under realistic, data-dependent scenarios.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.